Suresnes (France), December 5, 2023 – Servier, a global independent pharmaceutical group, announces the appointment of Nicolas Garnier as Chief Patient Officer, effective from December 4, 2023. He takes over from Bertrand Renaud, who will retire at the end of January 2024.
Reporting to Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs, Nicolas Garnier leads Global Patient Affairs department, whose mission is to integrate the voice of the patient at each stage of the drug lifecycle. His main objective is to coordinate, promote and develop patient engagement among all Group employees and global subsidiaries, working closely with patients and the organizations that represent them.
By doing this, Nicolas Garnier will continue the key work begun by Bertrand Renaud which aimed at reinforcing the patient culture within the Group and the dynamic of working collaboratively with patients and their organizations. The Group currently spearheads over 250 such initiatives, which address very real problems, from the phase of diagnosis to the correct use of treatment. Servier has also been ranked second this year on the list of the most reputed pharmaceutical companies working with oncology patient organizations, according to the PatientView Report 2022 survey.
“I am delighted about the arrival of Nicolas Garnier who will leverage his strong international experience gained in patient engagement and the understanding of their needs. He will also enable us to accelerate our desire to support patients in fighting their disease, giving them a central place in the diagnostic process, the development of new therapeutic solutions, and the adherence to their treatment.” declares Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs.
After completing a Degree in Cellular Biology and Physiology and a Specialized Masters in Genetics at Denis Diderot University in Paris, followed by a PhD in Experimental Medicine (Oncology) at McGill University in Montreal and a post-doc in Genomics (Pediatric Oncology) at the University of Montreal Faculty of Medicine, Nicolas began his professional career in 2015 as a Medical Advisor in the Rare Disease unit at Pfizer Canada. He quickly progressed towards roles that forged his understanding of patients in order to better integrate their voice at each stage of the drug lifecycle. Thus, he created the Pfizer Canada Patient Centricity Council and then in 2019 became Director of Patient Advocacy in the Global Product Development division of Pfizer Rare Disease in the US. In 2022 he was promoted to Senior Director of Patient Advocacy in Oncology & Rare Disease within Pfizer Global Product Development. From the start of this year and before joining the Servier Group, Nicolas was Head of Patient Advocacy in all therapeutic areas of Pfizer clinical studies.
Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, a source of inspiration every day.
As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting difficult and hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to Oncology. Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition.
Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.
For more information: servier.com